Global AI in drug discovery and screening market was valued at USD 364.67 million and is projected to reach a market size of USD 4000.56 million by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 40.8%.. Factors such as the increasing number of cross-industry collaborations and alliances are propelling artificial intelligence in the drug discovery market forward.
Market Overview
Artificial intelligence is a subfield of computer science concerned with simulating intelligent behavior. It allows computers to think and do tasks in the same way that humans and animals do, while also learning from their mistakes. Artificial intelligence is typically an algorithm designed to allow a computer to do tasks effectively while making minor mistakes. It applies deep learning and machine learning methods to personified knowledge while performing several activities.
Artificial intelligence has numerous applications in the drug development area, including tracking ailments, developing disease remedies, and predicting which animal viruses will change. Artificial intelligence has been shown to help researchers develop chronic disease remedies by enhancing R&D in medication discovery.
Drug discovery and development are processes in medicine, pharmacology, and biotechnology that involve discovering a biological target, such as an enzyme protein, gene, or receptor, and then designing, developing, and procuring a drug. The medications were previously found by determining the active ingredient in traditional treatments. As a result, drug discovery is the initial stage in identifying possible innovative medications and their therapeutic purposes. The bioavailability, effectiveness, potency, and toxicity of pharmaceuticals are now being assessed using new criteria.
Artificial intelligence has been widely used in the healthcare industry, particularly in the discovery of new medications. This can discover therapeutic targets, and it plays a key role in quickly identifying, producing, detecting, and screening small compounds. Furthermore, due to the advantages of adopting sophisticated techniques over traditional procedures, the market is predicted to increase at an exponential rate during the forecast period. Furthermore, an increasing number of industry alliances and partnerships are driving the market. Furthermore, artificial intelligence minimizes the cost and time spent in the drug discovery process, boosting the market growth. However, the market's expansion is hampered by a scarcity of trained individuals and data sets in the field of drug discovery. On the contrary, as people become more aware of artificial intelligence, manufacturers in the artificial intelligence for medication discovery and development market are projected to benefit significantly.
The ongoing Covid-19 epidemic has put a strain on existing healthcare systems and fuelled demand for new medicine remedies, prompting pharmaceutical companies to use AI-powered solutions in clinical trials and accelerate drug development both during and after the pandemic.
The COVID-19 pandemic has altered the landscape of the pharmaceutical industry, with substantial consequences for the full innovation and manufacturing value chain. During the epidemic, the number of patents has substantially decreased. The pharma industry's revenue has decreased substantially, and the number of employees has decreased overall.
MARKET DRIVERS
An increase in the number of cancer and other disease cases is estimated to boost the market growth.
Today Cancer has become one of the most common causes of mortality worldwide. Artificial Intelligence can assist researchers to understand how cancer cells acquire resistance to anticancer treatments in this area. Findings like these can assist researchers in creating and developing medications that are appropriate for the market. Furthermore, the significant need for medications to treat serious cancer is a factor that is helping AI in drug discovery grow.
Increased AI research and development activities are propelling market growth.
The market for artificial intelligence in drug research and development is booming, thanks to an increase in collaborations and cross-industry alliances. The importance of AI in medication discovery, as well as substantial financing for AI research and development, are anticipated to drive market expansion. Another factor boosting market demand is rising awareness of artificial intelligence and the significant potential in markets such as China and India.
MARKET RESTRAINTS
Market expansion in low-income countries is hampered by a lack of advanced instruments.
Artificial intelligence techniques may not be able to deal with the massive data sets available for drug development in pharmaceutical corporations, which contain millions of chemicals. Soon, this is predicted to stifle the growth of artificial intelligence in the drug discovery business.
The expensive cost of AI integration is limiting market expansion.
Artificial intelligence (AI) in the drug development market would be challenged by high costs associated with technology and technological restrictions. During the projection period of 2023 - 2030, however, a scarcity of skilled professionals and a lack of awareness will serve as a restraint, slowing the market's growth pace.
AI Drug Discovery & Screening MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 - 2030 |
|
Base Year |
2023 |
|
Forecast Period |
2024 - 2030 |
|
CAGR |
40.8% |
|
Segments Covered |
By Application, Therapeutics, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
IBM, Microsoft, Atomwise Inc., Cloud pharmaceuticals, Benevolent AI, BIO AGE |
This research report based on AI Drug Discovery & Screening Market is segmented and sub-segmented by application, Therapeutics, and region.
In 2021, the drug optimization and repurposing segment had the highest revenue share of nearly 50.0 percent, based on application. To evaluate undesirable drug effects and the overall efficacy of the drug, advanced AI systems such as Deep Learning (DL) and drug modeling can be applied. Advances in AI technology have also made it easier to research and compare medications, as well as repurpose them into more effective forms with fewer adverse effects and increased overall efficacy. This strategy is being utilized by the pharmaceutical industry to improve existing pharmaceuticals and to use them for different indications than they were previously used for, lowering development costs.
Another application of AI in drug development that is emerging at a rapid rate in preclinical testing. Manually selecting individuals based on their medical history and appropriateness for the trial can take a long time, but AI algorithms and associated technologies can shorten the drug's total clinical timeline. Based on genome-specific data, predictive machine learning algorithms can also help identify lead compounds and patient populations. Amplion employs its AI technology to carefully select biomarkers and assist its researchers in recruiting relevant patients and selecting the appropriate biomarkers, decreasing clinical study timelines.
In 2021, the oncology sub-segment had the highest revenue share of more than 20.0 percent. Because human mistake is common in disease diagnosis, AI systems can help with disease detection early on. In recent years, AI has improved its accuracy in detecting diseases. In this circumstance, earlier identification with the help of AI systems can prove to be an asset. Lung cancer is typically identified at later stages when survival rates are very low. A Northwestern University researcher was able to accurately detect lung cancer in scans that radiologists would have missed. By building on existing AI systems, which are meant to scan through massive data sets and generate relevant conclusions, AI can be utilized to give individualized treatments to patients. Scans, in combination with genetic sequences and patient histories, can be used to detect tumors early and to administer therapy tailored to the patients' needs.
From 2023 - 2030, the infectious diseases category is predicted to be the fastest-growing application segment. Artificial intelligence (AI) and related platforms such as the Internet of Things (IoT) are being used to better understand infectious illnesses, their transmission, and infection mechanisms, as well as to improve vaccine creation. These platforms rely on a network of linked devices, such as smartphones and other medical devices, to collect data that may be used to better understand lifestyle trends and anomalies, as well as to research diseases. In light of the current scenario, developing strategies for detecting infectious diseases has become increasingly important.
In 2021, North America had the highest revenue share of over 55.0 percent. The United States has been at the forefront of AI technology since its inception. IBM won a quiz game called 'Jeopardy' using their supercomputer 'Watson,' which led to the business development of the idea of AI since then. AI has become a big component of the IT industry, and it's being used all over the place, including in the pharmaceutical industry. Major American IT companies have partnered with prestigious institutes to accelerate medication discovery, design, and repurposing. They're also utilizing AI to research diseases and draw useful conclusions that will help with disease management.
From 2023 - 2030, the APAC market is predicted to grow at the quickest rate. AI is also being used by developing countries in the Asia Pacific to better understand diseases and improve drug research. Intuition Systems, an AI firm based in India, has partnered with Lantern Pharma on medication discovery and biomarker identification. Other AI businesses like Niramai and Sigtuple are working to improve healthcare by speeding up drug research and better identifying target proteins and biomarkers.
AI Drug Discovery & Screening by company
The need to find better treatments faster is boosting AI adoption in the pharmaceutical industry for illness research and drug development in general. Major IT companies are stepping up their efforts to speed up medication discovery. Corporations such as
control the majority of the global market share. Collaborations between tech businesses and academic and research institutions are providing the impetus for AI adoption in the pharmaceutical industry as a whole to grow. Better pharmaceuticals with less adverse effects can be developed, and diseases can be researched more quickly and thoroughly to uncover essential solutions with AI and related platforms. IBM Watson, Exscientia, GNS Healthcare, Alphabet (DeepMind), Benevolent AI, BioSymetrics, Euretos, Berg Health, Atomwise Intro, Cyclica, and others are some of the leading competitors in the worldwide artificial intelligence in the drug development industry.
RECENT DEVELOPMENTS IN THE AI Drug Discovery & Screening MARKET IN THE RECENT PAST.
In December 2021, Insilico Medicine, a medication development business driven by artificial intelligence (AI), stated that it had dosed the first healthy volunteer in a microdose trial of ISM 001-005. The medication is a small-molecule inhibitor of a biological target discovered by Pharma.AI and designed with AI. The experiment is currently underway in Australia.
In July 2021, Chief.AI, a machine learning platform, announced the launch of a pay-as-you-go AI platform for drug discovery. This platform enables SMEs to acquire affordable access to cutting-edge technology, reducing the hit-or-miss aspect of drug development and allowing for faster and more precise identification of breakthrough therapies.
In July 2021, Sanofi, the Paris-based pharmaceutical giant, entered into a research agreement with Exscientia, a company that utilizes artificial intelligence to find novel medication candidates and could be valued at up to $5.2 billion. The agreement represents a watershed moment for artificial intelligence-based drug discovery approaches, which have attracted billions of dollars in investment
in recent years on the promise of searching for novel medications far more efficient and risk-free, but have yet to deliver.
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
